Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models

• Mattia C. F. Prosperi ,

  * E-mail: ahnven@yahoo.it

  Affiliations Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, Informa CRO, Rome, Italy, College of Medicine, Pathology, Immunology and Laboratory Medicine, EPI, University of Florida, Gainesville, Florida, United States of America

  ⨯
• Michal Rosen-Zvi,

  Affiliation IBM Haifa Research Lab, Haifa, Israel

  ⨯
• André Altmann,

  Affiliation Max Planck Institute for Informatics, Saarbrücken, Germany

  ⨯
• Maurizio Zazzi,

  Affiliation University of Siena, Siena, Italy

  ⨯
• Simona Di Giambenedetto,

  Affiliation Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy

  ⨯
• Rolf Kaiser,

  Affiliation University of Cologne, Cologne, Germany

  ⨯
• Eugen Schülter,

  Affiliation University of Cologne, Cologne, Germany

  ⨯
• Daniel Struck,

  Affiliation Centre de Recherche Public-Santé, Luxembourg, Luxembourg

  ⨯
• Peter Sloot,

  Affiliation Universiteit van Amsterdam, Amsterdam, The Netherlands

  ⨯
• David A. van de Vijver,

  Affiliation Department of Virology, Erasmus MC, University Medical Centre Rotterdam, Utrecht, The Netherlands

  ⨯
• Anne-Mieke Vandamme,

  Affiliation Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium

  ⨯
• Anders Sönnerborg,

  Affiliation Karolinska Institute, Stockholm, Sweden

  ⨯
• for the EuResist and Virolab study groups